A modified TNM-based Japan Integrated Score combined with AFP level may serve as a better staging system for early-stage predominant hepatocellular carcinoma patients

Digestive and Liver Disease

Volumn 41, Issue 6, 2009, Pages 431-441

  Yen, Y H ^a   Changchien, C S ^a   Wang, J H ^a   Kee, K M ^a   Hung, C H ^a   Hu, T H ^a   Lee, C M ^a   Lin, C Y ^a   Wang, C C ^b   Chen, T Y ^b   Huang, Y J ^b   Lu, S N ^a  

^a CHANG GUNG MEMORIAL HOSPITAL   (Taiwan)

^b CHANG GUNG UNIVERSITY COLLEGE OF MEDICINE   (Taiwan)

Author keywords

Fetoprotein (AFP); Hepatocellular carcinoma; Japan Integrated Staging (JIS); Tumor Node Metastasis (TNM) staging

Indexed keywords

ALPHA FETOPROTEIN;

ADULT; ARTICLE; CANCER CLASSIFICATION; CANCER STAGING; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; EARLY CANCER; EARLY DIAGNOSIS; FEMALE; HUMAN; INTERMETHOD COMPARISON; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN BLOOD LEVEL;

ALPHA-FETOPROTEINS; CARCINOMA, HEPATOCELLULAR; EARLY DETECTION OF CANCER; FEMALE; HUMANS; LIVER NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; PROGNOSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 67349112109     PISSN: 15908658     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.dld.2008.11.008     Document Type: Article

References (28)

1. In: Fleming I.D., Cooper J.S., Henson D.E., Hutter R.V.P., Kennedy B.J., and Murphy G.P. (Eds). AJCC cancer staging manual. 5th ed. (1997), Lippincott-Raven, Philadelphia 294
2. Pugh R.N., Murray-Lyon I.M., Dawson J.L., Pietroni M.C., and Williams R. Transection of the oesophagus for bleeding esophageal varices. Br J Surg 60 (1973) 646-664
3. Tangkijvanich P., Anukulkarnkusol N., Suwangool P., Lertmaharit S., Hanvivatvong O., Kullavanijaya P., et al. Clinical characteristics and prognosis of hepatocellular carcinoma: analysis based on serum alpha-fetoprotein levels. J Clin Gastroenterol 31 (2000) 302-308
4. The Cancer of the Liver Italian Program (CLIP) Investigators. A new prognostic system for hepatocellular carcinoma: a retrospective study of 435 patients. Hepatology 28 (1998) 751-755
5. Llovet J.M., Bru C., and Bruix J. Prognosis of hepatocellular carcinoma: the BCLC staging classification. Semin Liver Dis 19 (1999) 329-337
6. Kudo M., Chung H., and Osaki Y. Prognostic staging system for hepatocellular carcinoma (CLIP score): its value and limitations, and a proposal for a new staging system, the Japan integrated staging score (JIS score). J Gastroenterol 38 (2003) 207-215
7. Liver Cancer Study Group of Japan. The General Rules for the Clinical and Pathological Study of Primary Liver Cancer. 3rd ed. (1992), Kanehara & Co., Ltd., Tokyo, Japan
8. Ueno S., Tanabe G., Nuruki K., Hamanoue M., Komorizono Y., Oketani M., et al. Prognostic performance of the new classification of primary liver cancer of Japan (4th edition) for patients with hepatocellular carcinoma: a validation analysis. Hepatol Res 24 (2002) 395-403
9. Poon R.T., and Fan S.T. Evaluation of the new AJCC/UICC staging system for hepatocellular carcinoma after hepatic resection in Chinese patients. Surg Oncol Clin N Am 12 (2003) 35-50
10. Vauthey J.N., Ribero D., Abdalla E.K., Jonas S., Bharat A., Schumacher G., et al. Outcomes of liver transplantation in 490 patients with hepatocellular carcinoma: validation of a uniform staging after surgical treatment. J Am Coll Surg 204 (2007) 1016-1027 discussion 1027-8
11. Kudo M., Chung H., Haji S., Osaki Y., Oka H., Seki T., et al. Validation of a new prognostic staging system for hepatocellular carcinoma: the JIS score compared with the CLIP score. Hepatology 40 (2004) 1396-1405
12. Toyoda H., Kumada T., Kiriyama S., Sone Y., Tanikawa M., Hisanaga Y., et al. Comparison of the usefulness of three staging systems for hepatocellular carcinoma (CLIP, BCLC, and JIS) in Japan. Am J Gastroenterol 100 (2005) 1764-1771
13. In: Greene F.L., Page D.L., Fleming I.D., Fritz A., Balch C.M., and Haller D.G. (Eds). AJCC cancer staging manual. 6th ed. (2002), Springer, Chicago 435
14. Kee K.M., Wang J.H., Lee C.M., Chen C.L., Changchien C.S., Hu T.H., et al. Validation of clinical AJCC/UICC TNM staging system for hepatocellular carcinoma: analysis of 5,613 cases from a medical center in southern Taiwan. Int J Cancer 120 (2007) 2650-2655
15. Chen C.H., Su W.W., Yang S.S., Chang T.T., Cheng K.S., Lin H.H., et al. Long-term trends and geographic variations in the survival of hepatocellular carcinoma patients: analysis of 11,312 patients in Taiwan. J Gastroenterol Hepatol 21 (2006) 1561-1566
16. Liaw Y.F., Tai D.I., Chu C.M., Lin D.Y., Sheen I.S., Chen T.J., et al. Early detection of hepatocellular carcinoma in patients with chronic type B hepatitis: a prospective study. Gastroenterology 90 (1986) 263-267
17. Ikai I. A modified Japan Integrated Stage score for prognostic assessment in patients with hepatocellular carcinoma. J Gastroenterol 41 (2006) 884-892
18. Akaike H. A new look at the statistical model identification. IEEE Trans Automatic Control AC-19 (1974) 716-723
19. Lai E.C., Fan S.T., Lo C.M., Chu K.M., Liu C.L., and Wong J. Hepatic resection for hepatocellular carcinoma: an audit of 343 patients. Ann Surg 221 (1995) 291-298
20. Cedrone A., Rapaccini G.L., Pompili M., Aliotta A., Trombino C., De Luca F., et al. Portal vein thrombosis complicating hepatocellular carcinoma. Value of ultrasound-guided fine-needle biopsy of the thrombus in the therapeutic management. Liver 16 (1996) 94-98
21. Liver Cancer Study Group of Japan. Survey and follow-up study of primary liver cancer in Japan-Report 11. Liver 36 (1995) 208-217
22. Cillo U., Vitale A., Grigoletto F., Farinati F., Brolese A., Zanus G., et al. Prospective validation of the Barcelona Clinic Liver Cancer staging system. J Hepatol 44 (2006) 723-731
23. Marrero J.A., Fontana R.J., Barrat A., Askari F., Conjeevaram H.S., Su G.L., et al. Prognosis of hepatocellular carcinoma: comparison of 7 staging systems in an American cohort. Hepatology 41 (2005) 707-716
24. Befeler A.S., and Di Bisceglie A.M. Hepatocellular carcinoma: diagnosis and treatment. Gastroenterology 122 (2002) 1609-1619
25. Llovet J.M., Fuster J., Bruix J., and of the Barcelona-Clinic Liver Cancer Group. The Barcelona approach: diagnosis, staging, and treatment of hepatocellular carcinoma. Liver Transpl 10 (2004) 115-120
26. Llovet J.M., Bruix J., and BCLC Group. Prospective validation of the Cancer of the Liver Italian Program (CLIP) score: a new prognostic system for patients with cirrhosis and hepatocellular carcinoma. Hepatology 32 (2000) 679-680
27. Changchien C.S., Chen C.L., Yen Y.H., Wang J.H., Hu T.H., Lee C.M., et al. An analysis of 6381 hepatocellular carcinoma patients in southern Taiwan: prognostic features, treatment outcome, and survival. J Gastroenterol 43 (2008) 159-170
28. Hu K.Q., Kyulo N.L., Lim N., Elhazin B., and Hillebrand D.J. Clinical significance of elevated alpha-fetoprotein (AFP) in patients with chronic hepatitis C, but not hepatocellular carcinoma. Am J Gastroenterol 99 (2004) 860-865